Transcript • Jan. 29, 2026 1:30 PM • Sanofi (SNY)
Transcript
Jan. 29, 2026 1:30 PM
Sanofi (SNY)
Alex Johnson: Well, what a year of achievements. We continue to focus on what matters most, breakthrough science that improves patients' lives. We delivered on that promise with strong results and full year guidance achieved. Here's what that journey looks like in numbers. First, we delivered strong performance and sales growth at 9.9%. We're particularly proud to have achieved a blockbuster milestone with our medicine for Haemophilia A. Second, our portfolio remains remarkably strong. Our newly launched products grew at strong double-digit rates, 34%, while our leading immunology medicine continues to deliver robust growth at 25%. We also brought new innovative options to patients through the successful launch of three new medicines and vaccines across haemophilia, ITP, and COVID-19. Third, we accelerated our diverse pipeline with multiple regulatory milestones and critical phase three readouts. Plus, five strategic acquisition announcements that are fueling our future growth. The progress we've made is real, but we still have work to do. A big thank you to all Synophians. None of this happens without you. Together, we're building the future of medicine as an R&D-driven, AI-powered biopharma company.
